home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences  
 

Understanding FDA and Avoiding Inspections Leading to Warning Letters, Seizures, Injunctions and Prosecutions

 
  September 04, 2013  
     
 
ComplianceOnline, Courtyard Philadelphia Downtown 21 N. Juniper Street
2013-09-18


Course Description:

Every company regulated by the U.S. FDA establishes procedures, practices and an internal monitoring system all designed to both meet the regulations and manage inspections. However, many are surprised by Warning letters or more serious actions. Regardless of whether your company has been on the receiving side of a regulatory action or not, this course will help you in have better Quality systems, effectively managing and responding to FDA inspections.

The first day will provide you with a better understanding of the FDA culture and the unique focus of FDA investigators during inspections. You will learn what are the observations and events that will signal to you that serious regulatory actions may follow. With prior knowledge, you can identify potentially serious deficiencies before an inspection in addition to responding quicker whenever serious issues are identified.

The key to being “inspection ready” are effective written procedures, training programs and monitoring including internal auditing. The instructor having more than 40 years of experience with FDA and the pharmaceutical industry will on the second day share his perspectives on what can be improved in these systems. If you believe that any Quality system can be improved or at least that it is important to constantly re-evaluate whether your own systems, you will benefit from attending.

Those benefiting include both those from the pharmaceutical and medical device industries. Events and observations from both industries will be used.

Learning Objectives:

  • Understanding FDA's enforcement strategy and what it means to your firm
  • Understanding how auditors think and their expectations
  • Being prepared to receive regulatory inspections
  • Recognizing when inspectional findings or events indicate potential regulatory actions
  • When to take or not immediate action during an inspection
  • Making better responses to FDA both during and following inspections
  • How to make written procedures and training more effective
  • How to increase the effectiveness and efficiency of internal audits
  • How to identify effective compliance metrics

 

 
 
Organized by: ComplianceOnline
Invited Speakers:

David Haggard
GMP Regulatory Consultant, David Haggard Associates LLC

David Haggard: Currently leads a consulting practice offering auditing, training and advising to small, medium and large pharmaceutical firms as a follow-up to a 30+ years’ experience with the U.S. FDA and 10+ years with Merck & Co., Inc. His experience with the FDA started as an investigator and advanced to supervisory investigator, director of the San Juan Puerto Rico Investigations branch, direction of FDA ORA’s inspection branch and finally as the director of the Office of Enforcement’ division of compliance policy.

 
Deadline for Abstracts: 2013-09-17
 
Registration: http://www.complianceonline.com/ecommerce/control/seminar?product_id=80078SEM&?channel=hummolgen
E-mail: referral@complianceonline.com
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.